Try

Dyne Therapeutics, Inc.

DYNUnited States

24 filed reports · 261 financial concepts · 0 earnings calls · 0 media appearances

Filed reports

24 reports · Sep 2020 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR182,173Sep 2020 to Jun 2026
Annual · 10-KSEC EDGAR61,808Dec 2020 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q210-QJun 30, 2026Jul 29, 2026285Open
FY2026 Q110-QMar 31, 2026May 11, 2026184Open
FY202510-KDec 31, 2025Mar 2, 2026610Open
FY2025 Q310-QSep 30, 2025Nov 5, 2025187Open
FY2025 Q210-QJun 30, 2025Jul 28, 2025115Open
FY2025 Q110-QMar 31, 2025May 8, 2025109Open
FY202410-KDec 31, 2024Feb 27, 2025262Open
FY2024 Q310-QSep 30, 2024Nov 12, 2024108Open
FY2024 Q210-QJun 30, 2024Aug 12, 202493Open
FY2024 Q110-QMar 31, 2024May 2, 2024103Open
FY202310-KDec 31, 2023Mar 5, 2024177Open
FY2023 Q310-QSep 30, 2023Oct 30, 2023106Open

Financial data

261 concepts · 3,981 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial259 concepts · 3,952 facts · Mar 2019 to Jul 2026

  • Restricted cash45 · Dec 2019 to Jun 2026
  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value37 · Mar 2019 to Jun 2026
  • Net income loss37 · Mar 2019 to Jun 2026
  • Stockholders equity (US GAAP)37 · Mar 2019 to Jun 2026
  • Allocated share based compensation expense35 · Sep 2019 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations35 · Sep 2019 to Jun 2026
  • Depreciation depletion and amortization35 · Sep 2019 to Jun 2026
  • General and administrative expense (US GAAP)35 · Sep 2019 to Jun 2026
  • Interest income other35 · Sep 2019 to Jun 2026
  • Operating expenses (US GAAP)35 · Sep 2019 to Jun 2026
  • Operating income loss35 · Sep 2019 to Jun 2026
  • Other nonoperating income expense35 · Sep 2019 to Jun 2026
  • Research and development expense35 · Sep 2019 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect34 · Dec 2019 to Jun 2026
  • Increase decrease in accounts payable and other operating liabilities34 · Dec 2019 to Jun 2026
  • Increase decrease in prepaid deferred expense and other assets34 · Dec 2019 to Jun 2026
  • Net cash provided by used in financing activities34 · Dec 2019 to Jun 2026
  • Net cash provided by used in investing activities34 · Dec 2019 to Jun 2026
  • Net cash provided by used in operating activities34 · Dec 2019 to Jun 2026
  • Payments to acquire property plant and equipment34 · Dec 2019 to Jun 2026
  • Profit loss34 · Dec 2019 to Jun 2026
  • Share based compensation34 · Dec 2019 to Jun 2026
  • Comprehensive income net of tax33 · Dec 2019 to Jun 2026
  • Accounts payable current32 · Dec 2019 to Jun 2026

Product1 concepts · 28 facts · Dec 2022 to Jun 2026

  • Research and development expense28 · Dec 2022 to Jun 2026

KPI1 concepts · 1 facts · Jun 2026

  • Clinical Trial Participants1 · Jun 2026

Segments

28 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or service2 members · 28 facts

  • DYNE-101 DM114 · Dec 2022 to Jun 2026
  • DYNE-251 DM114 · Dec 2022 to Jun 2026

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

Dyne Therapeutics, Inc. (DYN) data · FactIQ